| DSM 5 | Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition |
| ICD 11 | International Classification of Diseases 11th Revision |
| OCD | obsessive–compulsive disorder |
| PTSD | Post-traumatic stress disorder |
| SSRIs | Selective Serotonin Reuptake Inhibitors |
| SNRIs | Serotonin-Norepinephrine Reuptake Inhibitors |
| TCA | Tricyclic Antidepressants |
| 5 HT2A | 5 Hydroxytryptamine 2A receptor |
| BDNF | Brain Derived Neurotrophic Factor |
| CYP450 | Cytochrome P450 enzyme system |
| GI | Gastrointestinal |
| MAOIs | Monoamine Oxidase Inhibitors |
| NGF | Nerve Growth Factor |
| NMDA | N Methyl D Aspartate receptor |
| GABA | Gamma-Aminobutyric Acid |
| GABAA | Gamma-Aminobutyric Acid type A receptor |
| RCT | Randomized Controlled Trial |
| HPA axis | Hypothalamic–Pituitary–Adrenal axis |
| CNS | Central Nervous System |
| PD | Parkinson’s Disease |
| TCIM | Traditional, complementary, and integrative medicine |
| DDD | defined daily doses |
| NASSAs | noradrenaline and specific serotonergic antidepressants |
| LTLT | long-term lithium therapy |
| ADHD | attention deficit hyperactivity disorder |
| ALS | amyotrophic lateral sclerosis |
| MS | multiple sclerosis |
| LPS | lipopolysaccharide |
| CES-D | Center for Epidemiologic Studies Depression Scale |
| AP | alkaline phosphatase |
| BBB | blood–brain barrier |
| FST | Forced Swim Test |
| COX | cyclooxygenase |
| LOX | lipoxygenase |
| LA | linoleic acid |
| DHA | docosahexaenoic acid |
| ERGO | Ergothioneine |
| MCI | mild cognitive impairment |
| PD | Parkinson’s disease |
| AD | Alzheimer’s disease |
| AChE | Acetylcholinesterase |